Cepilimab is a novel PD-1 targeting monoclonal antibody with activity in squamous cell carcinoma of the skin
As reported at the ASCO 2018 meeting in Chicago, Migden et al report on athe results of the PD-1 targeting monoclonal antibody cemiplimab. was testing in a phase 1/2 clinical trial in patients with locally advanced and metastatic cutaneous squamous cell carcinoma of the skin. 26 patients in the phase 1 and 59 patients in the phase 2 trial were evaluated. All patients received 3mg/kg every 2 weeks. ORR was seen in 50% in the phase 1 and 47% in phase 2. 57% of patients had a response that lasted for more than 6 months. Fatigue was the most common adverse event reported in 27%,
In The Lancet Oncology , the phase 3 results fo the ARROW clinical trial were published earlier this week. There was an improvement in progression free survival in patients that were treated with once weekly higher dose carfilzomib than twice weekly lower dose. 478 patients with r/r MM from 118 sites were treated between September 2015 to August 2016. Patients were given 70mg/m2 once weekly versus 27 mg/m2 twice weekly. They were on 28 day cycles. Patients were also given 40mg of dexamethasonoe on days 1,8,15 and 22. The median progression free survival was 11.2 months versus 7.6 months.
ATR depletion has been implicated as a tumor targeting strategy in prior reports. In this study published by Thomas et al, the addition of a M6620 has shown an improvement in responsiveness to topotecan in a small phase I clinical trial. 21 patients with various different solid malignancies were enrolled in this study. The ATR-CHK2 pathway has been well implicated in promoting cancer cell survival. This is the first report of the combination of an ATR inhibitor in combination with a topoisomerase inhibitor. 2 patients had a partial response and 7 patients had stable disease of greater than 3 months duration. 1 grade 4 toxicity was seen.
In this phase 2 study published in JCO, researchers added everolimus to fulvestrant in female patients with stage IV breast CA, ER+ Her2 negative, that had progressed on an aromatase inhibitor. There was a 20% improvement in the clinical benefit rate as well as an improvement of 5 months in the median progression free survival.
News From PSMG
The latest news at Pacific Shores Medical Group
Disclaimer: This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, Pacific Shores Medical Group provides general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. Pacific Shores Medical Group is not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site.